Droplet Biosciences Cuts Cancer Genomic Analysis Time with NVIDIA GPUs
Droplet Biosciences has reduced its genomic analysis time for residual cancer detection by adopting NVIDIA's AI infrastructure, announced in a press release. The company's LymphDetect test, which identifies residual cancer in lymphatic fluid after tumor removal, now processes data significantly faster using NVIDIA Parabricks software.
By moving from CPU-based systems to GPU-accelerated workflows, Droplet shortened key bioinformatics steps substantially. Variant calling times dropped from up to 36 hours to under three hours, sequence alignment from around ten hours to under one, and overall analysis timelines from ten days to two days. These improvements are powered by NVIDIA's L4 Tensor Core and L40S GPUs.
Droplet noted that despite higher hourly GPU costs, the shorter runtime lowers the total cost per sample and supports scalability in clinical use. The company plans to further optimize its workflows with the goal of achieving one-day analysis for post-surgical cancer detection.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Sep 29 University Medical Center Göttingen Adopts MDClone Clinical Data Platform Sep 29 LUNGevity Awards $2 Million for Lung Nodule Risk Studies Sep 28 Deep Longevity to Launch Accrua Telehealth Platform in US Sep 28 United Imaging Intelligence Releases Medical Video AI Framework Sep 28 Orca Dental AI Brings CephX Imaging Tools to Planet DDS Cloud 9Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read moreYou may also like
Ultima Genomics Platform Selected for Precure's One Million Sample Dataset
LUNGevity Awards $2 Million for Lung Nodule Risk Studies
NYU Langone AI Uses Multiple 3D Mammograms to Predict Breast Cancer Risk
Linearis Joins Two Canadian AI Health Data Projects
Probably Genetic Gets Up to $10M ARPA-H Contract for Rare Disease AI
Daily AI Brief: the AI news that matters, in your inbox.